wound care technology News
-
BioLargo Adds Wound Management Expert and Former VP at Smith & Nephew, Tanya Rhodes, to Its Team
BioLargo, Inc. (OTCBB: BLGO) announced today that former Smith & Nephew Vice President of Innovation (and Vice President at Smith & Nephew Wound Management) Tanya Rhodes has joined the BioLargo management team as a senior strategy advisor. Rhodes will work closely with BioLargo and its recently formed medical subsidiary to commercialize its technology in the wound management and medical ...
-
Improving the Patient Experience: Before, During, and After Office Procedures
Improving dermatology patients’ experience during dermatology procedures means more than simply providing top-notch aesthetic treatment. It requires thoughtful interactions that address every aspect of the patient's visit including their physical comfort, emotional state, and socioeconomic status. Patients increasingly choose healthcare providers who can respond to their specific needs. ...
-
BioLargo Secures Financing for Its Advanced Wound Care Products Targeting FDA Application, Approval and Commercialization Through Its Subsidiary Clyra Medical Technologies
BioLargo, Inc. (OTCQB: BLGO) subsidiary Clyra Medical Technologies, Inc. has successfully concluded a financing from Sanatio Capital LLC for $750,000 in equity and a forward commitment to provide a $5,000,000 operating line of credit, to support the FDA approval and commercial launch of Clyra's advanced wound care products. Clyra Medical Technologies holds the exclusive license to commercialize ...
-
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
By healiva SA
-
Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane
Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you